Pharmaceutical Technology26d
Avutometinib potassium by Verastem for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to ...
Cancer Research1mon
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. 2Department of Radiation Oncology, University of California, San Francisco, San ...